Chairman & CEO of PsyBio Therapeutics, Evan Levine, shares why PsyBio doesn't use magic mushrooms to make psilocybin medicine.
Similar Posts
Real Estate and Psychedelic-Assisted Therapy with Ty Zakovich, Daniel Carcillo, and Cody Shandraw
In this episode David Flores, CEO of Spotlight Media Corp, sits down with the founding members of the newly formed Healing REIT that will focus on investing in real estate designed for innovative medicine such as psychedelic-assisted therapy.
Can Ketamine Therapy Be the Solution for Treatment Resistant Depression & Opioid Addiction?
Ketamine therapy is shaping up to be one of the…
Kanna: “Nature’s MDMA” feat. Stephanie Wang
In this episode, Sacha sits down with Stephanie Wang, the founder of KA! Empathogenics. They get into the exciting benefits Kanna, sometimes dubbed as ‘Nature’s MDMA’.
MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]
Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode.
Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating.
Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do?
Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s.
On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So….
In this segment, we’ll discuss FOUR possible cases:
Timestamps:
0:00 – Intro
4:17 – Worst Case
7:48 – Probable Case
9:57 – #WINNING CASE
11:58 – APES TOGETHER STRONG CASE
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
Psychedelic Sensuality and Womb Sovereignty with Mama de la Myco
In this episode, Dennis Walker and Mikaela de la Myco dive into the intersection of sex and psychedelics.
Psychedelic Spotlight Interview with Douglas K. Gordon
Psychedelic Spotlight Interview with Douglas K. Gordon In this episode…